CRAWLEY, UK, May 12, 2016 – The UK’s NHS Supply Chain (NHSSC) has signed an
order to acquire linear accelerators (linacs) and software from Elekta (EKTA
-B.ST) for a total value of GBP 21.5 million. The order was booked in the fourth
quarter of Elekta’s fiscal year (2015-16).
The order includes Elekta Synergy® (https://www.elekta.com/synergy) linacs with
Agility™ (https://www.elekta.com/agility) multileaf collimators for high speed
beam shaping. The Synergy linacs also include VMAT, which improves radiation
therapy treatment speed and dose reduction to the patient.
Andy Brown, Managing Director of NHS Supply Chain Capital Solutions, says: “The
Capital Team supports patient care by delivering the latest equipment at the
best value. These systems are a key part of delivering world class cancer care
and by using the Department of Health’s Capital Equipment fund to support the
bulk procurement with Elekta Ltd, we have released greater value for trusts and
savings back to the NHS.”
François Pointurier, Senior Vice President, Region Europe and AFLAME at Elekta
says: “This order comes on the tail of a recent study in the Green Journal
(Radiotherapy & Oncology) titled ‘Radiotherapy in Europe: An unmet need?’ Elekta
is delighted to be part of the solution by supporting the NHS in their
investment to address this situation and help improve the lives of patients with
cancer in the UK.”
Paddy Greally, Elekta’s Managing Director for the UK and Ireland, says: “Elekta
is delighted to continue our relationship with NHSSC and our long-term
commitment to radiotherapy in the UK. We are especially proud to deliver this
equipment to treat cancer from our international linac manufacturing site in
Crawley.”
All equipment and software will be delivered over the next 24 months.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on May 12, 2016.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.
